ArticleCurrent sleep medicine reports2026
Comorbid Insomnia and Sleep Apnea Mechanistic Convergence, Phenotypic Heterogeneity, and Clinical Implications.
Article in Current sleep medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Purpose of Review: Comorbid insomnia and obstructive sleep apnea (COMISA) is increasingly viewed as more than two coexisting sleep disorders. This review asks whether COMISA reflects a distinct phenotype driven by mechanistic convergence, how heterogeneous it is across patients, and what that means for diagnosis and treatment. Recent Findings: Recent studies show COMISA is common, linked to greater sleep fragmentation, and higher cardiometabolic and psychiatric burden than either disorder alone. Mechanistic work supports bidirectional interaction between ventilatory instability and chronic hyperarousal, with autonomic and EEG findings suggesting persistent sympathetic activation and cortical hyperactivation. Treatment studies indicate that PAP and CBT-I each help, but single-modality treatment often leaves residual symptoms; combined, phenotype-informed care appears more effective. Summary: The evidence supports COMISA as a clinically important, heterogeneous convergence phenotype rather than a simple comorbidity. Future research should prioritize longitudinal outcomes, biomarker-based phenotyping, and endotype-stratified trials. This shift could move COMISA care toward more precise, mechanism-guided management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.